In yesterday’s Wall Street session, Seagen Inc (NASDAQ:SGEN) shares traded at $228.74, down -0.07% from the previous session.
As we calculate the median target price by taking the range between a high of $229.00 and a low of $228.00, we find $229.00. Given the previous closing price of $228.90, this indicates a potential upside of 0.04 percent. SGEN stock price is now 6.49% away from the 50-day moving average and 13.09% away from the 200-day moving average. The market capitalization of the company currently stands at $43.15B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
Brokers who have rated the stock have averaged $228.90 as their price target over the next twelve months.
With the price target enhanced from $155 to $175, Raymond James Upgraded its rating from Outperform to Strong Buy for Seagen Inc (NASDAQ: SGEN).
In other news, Epstein David R, CEO sold 10,620 shares of the company’s stock on Nov 10. The stock was sold for $2,262,166 at an average price of $213.01. Upon completion of the transaction, the CEO now directly owns 136,598 shares in the company, valued at $31.25 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 09, Chief Technical Officer HIMES VAUGHN B sold 8,785 shares of the business’s stock. A total of $1,874,053 was realized by selling the stock at an average price of $213.32. This leaves the insider owning 42,574 shares of the company worth $9.74 million. Insiders disposed of 2,844,753 shares of company stock worth roughly $650.71 million over the past 1 year. A total of 0.70% of the company’s stock is owned by insiders.
Wednesday morning saw Seagen Inc (NASDAQ: SGEN) opened at $228.93. During the past 12 months, Seagen Inc has had a low of $123.77 and a high of $228.93. As of last week, the company has a debt-to-equity ratio of 0.05, a current ratio of 2.67, and a quick ratio of 2.12. The fifty day moving average price for SGEN is $214.81 and a two-hundred day moving average price translates $202.26 for the stock.
The latest earnings results from Seagen Inc (NASDAQ: SGEN) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$1.15, missing analysts’ expectations of -$0.79 by -0.36. This compares to -$1.03 EPS in the same period last year. The net profit margin was -32.61% and return on equity was -27.93% for SGEN. The company reported revenue of $648.65 million for the quarter, compared to $510.3 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 27.11 percent. For the current quarter, analysts expect SGEN to generate $684.61M in revenue.
Seagen Inc(SGEN) Company Profile
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
